Apr 02, 2020
ORIC Pharmaceuticals Appoints Christian V. Kuhlen, M.D., as General Counsel
Mar 02, 2020
ORIC Pharmaceuticals Appoints Mardi C. Dier to its Board of Directors
Jan 02, 2020
ORIC Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
Dec 02, 2019
ORIC Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference
Sep 10, 2019
ORIC Pharmaceuticals Appoints Dominic Piscitelli as Chief Financial Officer
Aug 28, 2019
ORIC to Participate in Citi's 14th Annual Biotech Investor Conference
Aug 08, 2019
ORIC Pharmaceuticals Announces Completion of $55 Million Mezzanine Financing to Advance Pipeline of Novel Therapies Targeting Cancer Resistance
Jul 09, 2019
ORIC Pharmaceuticals Appoints Lori Friedman, PhD, as Chief Scientific Officer
Apr 02, 2019
ORIC Pharmaceuticals Presents Evidence of Glucocorticoid Receptor-Mediated Cancer Treatment Resistance at the AACR Annual Meeting
Mar 06, 2019
ORIC Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
Mar 04, 2019
ORIC Pharmaceuticals Appoints Edna Chow Maneval, PhD, as Senior Vice President of Clinical Development
Feb 20, 2019
ORIC Pharmaceuticals to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
Jan 02, 2019
ORIC Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Nov 26, 2018
ORIC Pharmaceuticals Appoints Matt Panuwat as Chief Business Officer
Nov 19, 2018
ORIC Pharmaceuticals to Present at Upcoming Investor Conferences
Oct 22, 2018
ORIC to Participate at BTIG Biotech Conference
Sep 17, 2018
ORIC Pharmaceuticals Appoints Pratik Multani, MD, as Chief Medical Officer
Aug 30, 2018
ORIC to Participate at Citi 13th Annual Biotech Investor Conference
Feb 21, 2018
ORIC Pharmaceuticals Announces $50 Million Series C Financing to Support Novel Therapies for Treatment-Resistant Cancers
Oct 27, 2017
ORIC Pharmaceuticals Announces First Subject Dosed in Phase 1 Clinical Study of Novel GR Antagonist with Planned Development for Oncology